MX383665B - Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. - Google Patents

Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.

Info

Publication number
MX383665B
MX383665B MX2016010179A MX2016010179A MX383665B MX 383665 B MX383665 B MX 383665B MX 2016010179 A MX2016010179 A MX 2016010179A MX 2016010179 A MX2016010179 A MX 2016010179A MX 383665 B MX383665 B MX 383665B
Authority
MX
Mexico
Prior art keywords
donepezil
disease
compositions
methods
treating alzheimer
Prior art date
Application number
MX2016010179A
Other languages
English (en)
Spanish (es)
Other versions
MX2016010179A (es
Inventor
Ashok Katdare
Kavita Vermani
Mahendra G Dedhiya
Original Assignee
Forest Laboratories Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53753905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX383665(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Laboratories Holdings Ltd filed Critical Forest Laboratories Holdings Ltd
Publication of MX2016010179A publication Critical patent/MX2016010179A/es
Publication of MX383665B publication Critical patent/MX383665B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
MX2016010179A 2014-02-04 2015-02-04 Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. MX383665B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461935596P 2014-02-04 2014-02-04
PCT/US2015/014404 WO2015120013A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and method of treating alzheimer's disease

Publications (2)

Publication Number Publication Date
MX2016010179A MX2016010179A (es) 2017-04-06
MX383665B true MX383665B (es) 2025-03-14

Family

ID=53753905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010179A MX383665B (es) 2014-02-04 2015-02-04 Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.

Country Status (7)

Country Link
US (2) US20150216849A1 (enExample)
EP (1) EP3102186B1 (enExample)
JP (2) JP6604957B2 (enExample)
CA (2) CA2938671A1 (enExample)
IL (2) IL247092B (enExample)
MX (1) MX383665B (enExample)
WO (1) WO2015120013A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2938671A1 (en) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and method of treating alzheimer's disease
WO2018035157A1 (en) * 2016-08-15 2018-02-22 Axovant Sciences Gmbh Compositions and methods of treating a neurodegenerative disease
CN109803654B (zh) * 2017-02-23 2022-06-28 上海华汇拓医药科技有限公司 一种多奈哌齐半帕莫酸盐的粉针剂、包含其的组合物及它们的制备方法
WO2020068731A1 (en) * 2018-09-25 2020-04-02 The General Hospital Corporation Methods for integrating cell gene expression data from multiple single-cell data sets and uses thereof
WO2020208398A1 (es) * 2019-04-09 2020-10-15 Laboratorios Bagó S.A. Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10966989B2 (en) * 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
WO2022270663A1 (ko) * 2021-06-23 2022-12-29 동아에스티 주식회사 도네페질, 실로스타졸 및 아리피프라졸을 포함하는 치매, 인지장애 또는 혈관성 우울증의 예방, 개선 또는 치료용 약학적 조성물
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
WO2023128890A1 (en) * 2021-12-28 2023-07-06 Ilko Ilac Sanayi Ve Ticaret A.S. Donepezil – memantine extended release capsule composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EA012220B1 (ru) 2004-10-19 2009-08-28 Крка, Товарна Здравил, Д. Д., Ново Место Твёрдая фармацевтическая композиция, содержащая донепезила гидрохлорид
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
JP5597343B2 (ja) * 2005-04-28 2014-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有する組成物
WO2007055329A1 (ja) * 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
EP2583669A1 (en) 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
TWI491395B (zh) 2009-09-30 2015-07-11 Ct Lab Inc 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
CN102309465B (zh) 2010-06-30 2015-04-22 天津药物研究院 含盐酸多奈哌齐活性成分的缓释片及其制备方法和用途
TR201007110A2 (tr) * 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
WO2013005094A1 (en) * 2011-07-05 2013-01-10 Torrent Pharmaceuticals Ltd Acid addition salt of donepezil and pharmaceutical composition thereof
CA2938671A1 (en) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and method of treating alzheimer's disease

Also Published As

Publication number Publication date
JP6604957B2 (ja) 2019-11-13
MX2016010179A (es) 2017-04-06
CA2938671A1 (en) 2015-08-13
WO2015120013A1 (en) 2015-08-13
EP3102186A1 (en) 2016-12-14
JP2017506624A (ja) 2017-03-09
US20180169082A1 (en) 2018-06-21
IL276315A (en) 2020-09-30
US20150216849A1 (en) 2015-08-06
JP2020037556A (ja) 2020-03-12
IL247092A0 (en) 2016-09-29
IL247092B (en) 2020-08-31
EP3102186B1 (en) 2021-01-27
CA3214846A1 (en) 2015-08-13
EP3102186A4 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MX2024010140A (es) Nuevos metodos.
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
MX387322B (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MX392677B (es) Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes.
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PT3215143T (pt) Combinação compreendendo espirulina e palmitoíletanolamida
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
ZA201905309B (en) Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals
PL3300730T3 (pl) Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać leku
HRP20211309T1 (hr) N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti
PH12018500221A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
EA202090452A1 (ru) Соединения для лечения болезни фон гиппеля-линдау
TH167850A (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
HK1231763A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders